Literature DB >> 7452508

Pharmacokinetics, covalent binding and subcellular distribution of [3H]doxorubicin after intravenous administration in the mouse.

B J Marafino, S N Giri, D M Siegel.   

Abstract

Some aspects of the in vivo disposition of [3H]doxorubicin were investigated in mice in the first 6 hr after a 5 mg/kg i.v. dose. The disappearance of radioactivity from plasma and erythrocytes was consistent with biphasic kinetics. Highest peak radioactivity was found in lung, liver and kidney. Retention half-lives of radioactivity in heart, lung, kidney and small intestine were between 4.5 to 6.5 hr, while in liver, adrenal gland and spleen they were 7 to 13 hr and in skeletal muscle and bone marrow were 17 and 35 hr, respectively. Radioactivity in pancreas and epididymal fat had not equilibrated by 6 hr, and brain and testicle contained little radioactivity. Exhaustive methanol-ether extraction of acid-precipitated homogenates showed covalent binding of radioactivity to lung, liver, kidney and spleen at 40 to 100 pmol/mg of protein, while binding in plasma, small intestine and pancreas ranged from 4 to 30 pmol/mg of protein; heart and skeletal muscle showed 0 to 1.4 pmol/mg of protein at all times examined. Differential centrifugation revealed no site of subcellular accumulation within liver, kidney or most notably heart, other than the nuclear fraction. Specific levels of drug were highest in nuclei of liver, requiring 45 min to reach peak amounts; the lowest quantity per milligram of nuclear protein was found in the heart, and had already peaked by 10 min. These results suggest that the cardiotoxicity of doxorubicin may not be due to concentration or retention of drug within heart tissue as a whole or any non-nuclear subcellular fraction of it nor to the covalent binding of drug to heart protein, but may follow directly from the interaction of doxorubicin with the cardiac nuclei.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7452508

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Treatment of Invasive Brain Tumors Using a Chain-like Nanoparticle.

Authors:  Pubudu M Peiris; Aaron Abramowski; James Mcginnity; Elizabeth Doolittle; Randall Toy; Ramamurthy Gopalakrishnan; Shruti Shah; Lisa Bauer; Ketan B Ghaghada; Christopher Hoimes; Susann M Brady-Kalnay; James P Basilion; Mark A Griswold; Efstathios Karathanasis
Journal:  Cancer Res       Date:  2015-01-27       Impact factor: 12.701

2.  Enhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radio-frequency-tunable drug release.

Authors:  Pubudu M Peiris; Lisa Bauer; Randall Toy; Emily Tran; Jenna Pansky; Elizabeth Doolittle; Erik Schmidt; Elliott Hayden; Aaron Mayer; Ruth A Keri; Mark A Griswold; Efstathios Karathanasis
Journal:  ACS Nano       Date:  2012-04-13       Impact factor: 15.881

Review 3.  Crossing the barrier: treatment of brain tumors using nanochain particles.

Authors:  Efstathios Karathanasis; Ketan B Ghaghada
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-09

4.  Doxorubicin binds in a cooperative manner to myocardial cells. Two binding sites.

Authors:  K Wassermann; E Steiness
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Treatment of cancer micrometastasis using a multicomponent chain-like nanoparticle.

Authors:  Pubudu M Peiris; Randall Toy; Aaron Abramowski; Pete Vicente; Samantha Tucci; Lisa Bauer; Aaron Mayer; Morgan Tam; Elizabeth Doolittle; Jenna Pansky; Emily Tran; Dishen Lin; William P Schiemann; Ketan B Ghaghada; Mark A Griswold; Efstathios Karathanasis
Journal:  J Control Release       Date:  2013-11-02       Impact factor: 9.776

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.